FCPM III Services’s enGene Therapeutics ENGN Stock Holding History

FCPM III Services’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.6M	Hold	9,632,561	–	–	9.08%	4
2025 Q4	$87M	Hold	9,632,561	–	–	11.4%	3
2025 Q3	$65.8M	Hold	9,632,561	–	–	13.15%	3
2025 Q2	$35.1M	Hold	9,632,561	–	–	9.5%	4
2025 Q1	$43.2M	Hold	9,632,561	–	–	10.43%	3
2024 Q4	$64.1M	Buy	9,632,561 +954,610	+11%	+$7.41M	10.81%	3
2024 Q3	$57.3M	Hold	8,677,951	–	–	9.84%	3
2024 Q2	$81.8M	Hold	8,677,951	–	–	12.07%	3
2024 Q1	$147M	Hold	8,677,951	–	–	20.79%	3
2023 Q4	$80.1M	Buy	+8,677,951	New	+$76.8M	23.6%	3

Other funds holding ENGN

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return